Mirati Therapeutics ROE 2024

Mirati Therapeutics Aktienanalyse

What does Mirati Therapeutics do?

Mirati Therapeutics Inc is a biotechnology company based in San Diego, California, that focuses on the discovery and development of personalized therapies for cancer. The company was founded in 1995 and originally focused on developing drugs for the treatment of inflammatory diseases. However, in 2012, the company changed its strategy and began to focus on cancer therapies. Mirati Therapeutics' business model is based on the discovery and development of drugs for cancer patients with specific genetic mutations or abnormalities. The company utilizes new insights in cancer genomics to develop targeted therapeutic approaches tailored to the specific needs of cancer patients. The company operates in three different business areas: preclinical research, clinical development, and commercial products. In the preclinical research area, the company focuses on investigating new target candidates and identifying potential drugs for the treatment of cancer. Clinical development involves conducting clinical trials to evaluate the effectiveness and safety of drugs in relation to specific types of cancer. The company also works on marketing and selling commercial products that are already approved on the market and used for the treatment of cancer. One of Mirati Therapeutics' products is the drug Adagrasib, a treatment for patients with advanced non-small cell lung cancer (NSCLC) and specific genetic mutations. Adagrasib aims to inhibit the activity of KRAS, an oncogene that is overexpressed in many types of cancer. The company also has other drugs in the pipeline that are still in preclinical or clinical development. Mirati Therapeutics has partnerships with other companies in the biotech and pharmaceutical industries to advance the discovery and development of new therapies. In 2020, the company announced a strategic collaboration with the pharmaceutical company Amgen to combine Amgen's KRAS inhibitor portfolio with Mirati's and receive milestone payments. The company works closely with the FDA and other regulatory authorities to obtain approval for new drugs and demonstrate the safety and efficacy of its products. The company has made significant progress in the development of personalized cancer therapies in recent years and hopes to be able to help even more patients in the future. In summary, Mirati Therapeutics Inc is an innovative biotechnology company that focuses on the discovery and development of personalized cancer therapies. The company collaborates closely with other industry partners to develop and bring new drugs to the market. Mirati Therapeutics strives to improve the lives of cancer patients and hopes to offer even more innovative therapies in the future. Mirati Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Mirati Therapeutics's Return on Equity (ROE)

Mirati Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Mirati Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Mirati Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Mirati Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Mirati Therapeutics stock

What is the ROE (Return on Equity) of Mirati Therapeutics this year?

The ROE of Mirati Therapeutics this year is -0.74 undefined.

How has the Return on Equity (ROE) of Mirati Therapeutics developed compared to the previous year?

The ROE of Mirati Therapeutics has increased by 78.53% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Mirati Therapeutics?

A high ROE indicates that Mirati Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Mirati Therapeutics?

A low ROE can indicate that Mirati Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Mirati Therapeutics affect the company?

A change in ROE (Return on Equity) of Mirati Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Mirati Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Mirati Therapeutics?

Some factors that can influence Mirati Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Mirati Therapeutics pay?

Over the past 12 months, Mirati Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mirati Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Mirati Therapeutics?

The current dividend yield of Mirati Therapeutics is .

When does Mirati Therapeutics pay dividends?

Mirati Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mirati Therapeutics?

Mirati Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Mirati Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mirati Therapeutics located?

Mirati Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mirati Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mirati Therapeutics from 10/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Mirati Therapeutics pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Mirati Therapeutics in the year 2023?

In the year 2023, Mirati Therapeutics distributed 0 USD as dividends.

In which currency does Mirati Therapeutics pay out the dividend?

The dividends of Mirati Therapeutics are distributed in USD.